Literature DB >> 16437583

Severe episodic neurological deficits and permanent mental retardation in a child with a novel FHM2 ATP1A2 mutation.

K R J Vanmolkot1, H Stroink, J B Koenderink, E E Kors, J J M W van den Heuvel, E H van den Boogerd, A H Stam, J Haan, B B A De Vries, G M Terwindt, R R Frants, M D Ferrari, A M J M van den Maagdenberg.   

Abstract

OBJECTIVE: Attacks of familial hemiplegic migraine (FHM) are usually associated with transient, completely reversible symptoms. Here, we studied the ATP1A2 FHM2 gene in a young girl with episodes of both very severe and transient neurological symptoms that were triggered by mild head trauma as well as permanent mental retardation. Her family members suffered from hemiplegic and confusional migraine attacks.
METHODS: Mutation analysis of the ATP1A2 gene was performed by direct sequencing of all exons and flanking intronic regions, using genomic DNA of the proband. Functional consequences of the mutation were analyzed by cellular survival assays.
RESULTS: We identified a novel G615R ATP1A2 mutation in the proband and several of her family members. Functional analysis of mutant Na,K-ATPase in cellular survival assays showed a complete loss-of-function effect.
INTERPRETATION: Permanent mental retardation in children may be caused by ATP1A2 mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16437583     DOI: 10.1002/ana.20760

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  21 in total

Review 1.  [Genetics of migraine].

Authors:  T Freilinger; M Dichgans
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

2.  Prolonged hemiplegic episodes in children due to mutations in ATP1A2.

Authors:  J C Jen; A Klein; E Boltshauser; M S Cartwright; E S Roach; H Mamsa; R W Baloh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05       Impact factor: 10.154

3.  The structure of the Na+,K+-ATPase and mapping of isoform differences and disease-related mutations.

Authors:  J Preben Morth; Hanne Poulsen; Mads S Toustrup-Jensen; Vivien Rodacker Schack; Jan Egebjerg; Jens Peter Andersen; Bente Vilsen; Poul Nissen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-01-27       Impact factor: 6.237

4.  Recurrent ATP1A2 mutations in Portuguese families with familial hemiplegic migraine.

Authors:  Maria-José Castro; Anine H Stam; Carolina Lemos; José Barros; Raquel G Gouveia; Isabel Pavão Martins; Jan B Koenderink; Kaate R J Vanmolkot; Alexandre P Mendes; Rune R Frants; Michel D Ferrari; Jorge Sequeiros; José M Pereira-Monteiro; Arn M J M van den Maagdenberg
Journal:  J Hum Genet       Date:  2007-10-19       Impact factor: 3.172

5.  Familial and sporadic hemiplegic migraine: diagnosis and treatment.

Authors:  Nadine Pelzer; Anine H Stam; Joost Haan; Michel D Ferrari; Gisela M Terwindt
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

Review 6.  Molecular genetics of migraine.

Authors:  Boukje de Vries; Rune R Frants; Michel D Ferrari; Arn M J M van den Maagdenberg
Journal:  Hum Genet       Date:  2009-05-20       Impact factor: 4.132

7.  Acute encephalopathy in familial hemiplegic migraine with ATP1A2 mutation.

Authors:  Aine Merwick; Desiree Fernandez; Brian McNamara; Hugh Harrington
Journal:  BMJ Case Rep       Date:  2013-06-10

8.  Diverse functional consequences of mutations in the Na+/K+-ATPase alpha2-subunit causing familial hemiplegic migraine type 2.

Authors:  Neslihan N Tavraz; Thomas Friedrich; Katharina L Dürr; Jan B Koenderink; Ernst Bamberg; Tobias Freilinger; Martin Dichgans
Journal:  J Biol Chem       Date:  2008-08-26       Impact factor: 5.157

9.  Novel mutations affecting the Na, K ATPase alpha model complex neurological diseases and implicate the sodium pump in increased longevity.

Authors:  Lesley J Ashmore; Stacy L Hrizo; Sarah M Paul; Wayne A Van Voorhies; Greg J Beitel; Michael J Palladino
Journal:  Hum Genet       Date:  2009-05-12       Impact factor: 4.132

Review 10.  Familial hemiplegic migraine.

Authors:  Daniela Pietrobon
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.